Literature DB >> 9637722

Phenylketonuria. The in vivo hydroxylation rate of phenylalanine into tyrosine is decreased.

F J van Spronsen1, D J Reijngoud, G P Smit, G T Nagel, F Stellaard, R Berger, H S Heymans.   

Abstract

In phenylketonuria (PKU), the enzyme phenylalanine hydroxylase is deficient, resulting in a decreased conversion of phenylalanine (Phe) into tyrosine (Tyr). The severity of the disease is expressed as the tolerance for Phe at 5 yr of age. In PKU patients it is assumed that the decreased conversion of Phe into Tyr is directly correlated with the tolerance for Phe. We investigated this correlation by an in vivo stable isotope study. The in vivo residual hydroxylation was quantitated using a primed continuous infusion of L-[ring- 2H5]Phe and L-[1-13C]Tyr and the determination of the isotopic enrichments of L-[ring-2H5]Phe, L-[ring-2H4]Tyr, and L-[1-13C]Tyr in plasma. Previous reports by Thompson and coworkers (Thompson, G.N., and D. Halliday. 1990. J. Clin. Invest. 86:317-322; Thompson, G.N., J.H. Walter, J.V. Leonard, and D. Halliday. 1990. Metabolism. 39:799-807; Treacy, E., J.J. Pitt, K. Seller, G.N. Thompson, S. Ramus, and R.G.H. Cotton. 1996. J. Inherited Metab. Dis. 19:595- 602), applying the same technique, showed normal in vivo hydroxylation rates of Phe in almost all PKU patients. Therefore, our study was divided up in two parts. First, the method was re-evaluated. Second, the correlation between the in vivo hydroxylation of Phe and the tolerance for Phe was tested in seven classical PKU patients. Very low (0.13- 0.95 micromol/kg per hour) and normal (4.11 and 6.33 micromol/kg per hour) conversion rates were found in patients and controls, respectively. Performing the infusion study twice in the same patient and wash-out studies of the labels at the end of the experiment in a patient and control showed that the method is applicable in PKU patients and gives consistent data. No significant correlation was observed between the in vivo hydroxylation rates and the tolerances. The results of this study, therefore, showed that within the group of patients with classical PKU, the tolerance does not depend on the in vivo hydroxylation.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9637722      PMCID: PMC508879          DOI: 10.1172/JCI737

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  17 in total

1.  In vivo enzyme activity in inborn errors of metabolism.

Authors:  G N Thompson; J H Walter; J V Leonard; D Halliday
Journal:  Metabolism       Date:  1990-08       Impact factor: 8.694

2.  Phenylalaninaemia. Differential diagnosis.

Authors:  M E Blaskovics; G E Schaeffler; S Hack
Journal:  Arch Dis Child       Date:  1974-11       Impact factor: 3.791

3.  In vivo disposal of phenylalanine in phenylketonuria: a study of two siblings.

Authors:  E Treacy; J J Pitt; K Seller; G N Thompson; S Ramus; R G Cotton
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

4.  Analysis of phenylalanine hydroxylase genotypes and hyperphenylalaninemia phenotypes using L-[1-13C]phenylalanine oxidation rates in vivo: a pilot study.

Authors:  E P Treacy; J J Delente; G Elkas; K Carter; M Lambert; P J Waters; C R Scriver
Journal:  Pediatr Res       Date:  1997-10       Impact factor: 3.756

5.  Significant phenylalanine hydroxylation in vivo in patients with classical phenylketonuria.

Authors:  G N Thompson; D Halliday
Journal:  J Clin Invest       Date:  1990-07       Impact factor: 14.808

6.  Plasma and urine enrichments following infusion of L-[1-13C]phenylalanine and L-[ring-2H5]phenylalanine in humans: evidence for an isotope effect in renal tubular reabsorption.

Authors:  G A Zello; L Marai; A S Tung; R O Ball; P B Pencharz
Journal:  Metabolism       Date:  1994-04       Impact factor: 8.694

7.  Plasma phenylalanine and tyrosine responses to different nutritional conditions (fasting/postprandial) in patients with phenylketonuria: effect of sample timing.

Authors:  F J van Spronsen; M van Rijn; T van Dijk; G P Smit; D J Reijngoud; R Berger; H S Heymans
Journal:  Pediatrics       Date:  1993-10       Impact factor: 7.124

8.  Phenylalanine conversion to tyrosine: comparative determination with L-[ring-2H5]phenylalanine and L-[1-13C]phenylalanine as tracers in man.

Authors:  J S Marchini; L Castillo; T E Chapman; J A Vogt; A Ajami; V R Young
Journal:  Metabolism       Date:  1993-10       Impact factor: 8.694

9.  Relation between genotype and phenotype in Swedish phenylketonuria and hyperphenylalaninemia patients.

Authors:  E Svensson; U von Döbeln; R C Eisensmith; L Hagenfeldt; S L Woo
Journal:  Eur J Pediatr       Date:  1993-02       Impact factor: 3.183

10.  Molecular basis of phenylketonuria and a correlation between genotype and phenotype in a heterogeneous southeastern US population.

Authors:  R C Eisensmith; D R Martinez; A I Kuzmin; A A Goltsov; A Brown; R Singh; I I Elsas LJ; S L Woo
Journal:  Pediatrics       Date:  1996-04       Impact factor: 7.124

View more
  6 in total

Review 1.  Uses of stable isotopes in clinical diagnosis and research in the paediatric population.

Authors:  O A Bodamer; D Halliday
Journal:  Arch Dis Child       Date:  2001-05       Impact factor: 3.791

2.  Modelling the phenylalanine blood level response during treatment of phenylketonuria.

Authors:  U Langenbeck; J Zschocke; U Wendel; V Hönig
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

3.  A model of human phenylalanine metabolism in normal subjects and in phenylketonuric patients.

Authors:  S Kaufman
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-16       Impact factor: 11.205

4.  An ongoing debate over phenylalanine hydroxylase deficiency in phenylketonuria.

Authors:  C R Scriver
Journal:  J Clin Invest       Date:  1998-06-15       Impact factor: 14.808

Review 5.  Flux analysis of inborn errors of metabolism.

Authors:  D-J Reijngoud
Journal:  J Inherit Metab Dis       Date:  2018-01-09       Impact factor: 4.982

6.  Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation.

Authors:  Richard W D Welford; Magali Vercauteren; Annette Trébaul; Christophe Cattaneo; Doriane Eckert; Marco Garzotti; Patrick Sieber; Jérôme Segrestaa; Rolf Studer; Peter M A Groenen; Oliver Nayler
Journal:  Sci Rep       Date:  2016-07-21       Impact factor: 4.379

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.